ALTER — Theradiag SA Share News
0.000.00%
Last trade - 00:00- €16.44m
- €12.36m
- €12.20m
Brief: Theradiag Gets Approval For New I-Track10 Automated Analyzer For Biotherapy Monitoring
Brief: Theradiag Announces Agreement With Predictimmune For Commercialization Of PredictSURE IBD™
Brief: Theradiag H1 Operating Loss Stable At 0.2 Million Euros
Brief: Theradiag H1 Revenue Increases to EUR 5.0 MLN
Brief: Theradiag SA Signs A New Contract With Haliodx, A French Expert Specialized In Innovative Diagnosis Of Digestive System Diseases
Brief: Theradiag And HOB Biotech Settle Their Legal Dispute
Brief: Theradiag Signs A Development And Distribution Agreement With Immunodiagnostic Systems
Brief: Theradiag FY Operating Loss Narrows To 0.6 Million Euros
Brief: Theradiag FY Consolidated Revenue Is At 8.9 Million Euros
Brief: Theradiag Says Cosentyx Gets CE Mark
Brief: Theradiag Appoints Bertrand De Castelnau As Chief Executive Officer
Brief: Theradiag Appoints Pierre Morgon As Chairman Of The Board
Brief: Theradiag Revenue At End-Sept Down At EUR 6.5 Million
Brief: Theradiag Announces Departure Of CEO Michel Finance
Brief: Theradiag H1 Net Loss Narrows To 89,000 Euros
Brief: Theradiag FY Operating Loss Widens To 2.5 Million Euros
Brief: Theradiag And Biogaran Sign A Partnership Agreement
Brief: Theradiag And Biogaran Sign A Partnership Agreement
Brief: Theradiag FY Revenue Up at 9.1 Million Euros